PD-1/PD-L1 Antibody versus Gefitinib for Advanced Non-small Cell Lung Cancer: A Systematic Review and Network Meta-analysis of Randomized Control Trials


School of Basic Medicine, Air Force Military Medical University, Xiían, Shanxxi, China.
PD-1/PD-L1 antibody and gefitinib have made much progress in treatment of advanced non-small cell lung cancer. Recent randomized control trials revealed that both of them exhibited effective outcomes after first-line treatment, especially compared to chemotherapy. However, it is unknown that whatís the efficacy and safety between them due to lacking of direct evidences. Relevant randomized control trials were selected by searching electronic databases (PubMed, Embase, and Cochrane Library) and reference lists of related articles by hand. This study has been registered at International Prospective Register of Systematic Reviews (number CRD42018094297). According to Cochrane Handbook, two reviewers independently assessed eligibility and quality of the studies. The outcome measures were overall survival, progression-free survival, objective response rate and adverse events calculated through the fixed random effect model. PD-1/PD-L1 antibody could improve overall survival [HR=0.69(0.61-0.77), P=0.000] significantly over gefitinib, no matter of West Country, orient country and different PD-1/PD-L1 antibodies. While there was no significant difference between them in progression-free survival [HR=0.92(0.78-1.09), P=0.352] and objective response rate [HR=0.86(0.50-1.49), P=0.587]. Subgroup analysis suggested that PD-1/PD-L1 antibody could improve progression-free survival only for West Country [HR=0.83(0.71-0.96), P=0.010], and for objective response rate, similar results appeared only for orient country [HR=0.16(0.05-0.49), P=0.001] and atezolizumab [HR=0.50(0.27-0.94), P=0.031]. For incidence of adverse events, PD-1/PD-L1 antibody could reduce risk of nausea (all grades) [RR=0.65 (0.44-0.97), p=0.035], neutropenia (=3 grade) [RR=0.30 (0.09-0.93), p=0.038], diarrhoea (all grades, =3 grade) [RR=0.26 (0.18-0.38), p=0.000, 0.23(0.08-0.67), p=0.007], rash (all grades) [RR=0.35 (0.14-0.84), p=0.019] and leukopenia (=3 grade) [RR=0.19 (0.04-0.80), p=0.024] over gefitinib, but increase risk of fatigue (all grades) [RR=1.72 (1.18-2.49), p=0.004]. PD-1/PD-L1 monoclonal antibody is superior to gefitinib for overall survival for the after-first-line treatment of advanced NSCLC in general. Further considering survival and incidence of adverse events comprehensively, relative to gefitinib, PD-1/PD-L1 monoclonal antibody may be a better choice for advanced NSCLC.
Biaoxue R, Shuanying Y, Wei L et al., 2012. Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients. Curr Med Res Opin, 28, 1699-1708.
Borghaei H, Paz-Ares L, Horn L et al., 2015. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med, 373, 1627-1639.
Brahmer J, Reckamp KL, Baas P et al., 2015. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med, 373,123-135.
Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K et al., 2006. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs, 17, 401-409.
Fehrenbacher L, Spira A, Ballinger M, et al., 2016. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet, 387, 1837-1846.
Gettinger SN, Horn L, Gandhi L, et al., 2015. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients with Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol, 33, 2004-2012
Herbst RS, Baas P, Kim DW et al., 2016. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, 387, 1540-1550.
Hida T, Kaji R, Satouchi M, et al., 2018. Atezolizumab in Japanese Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study. Clin Lung Cancer, 19(4), e405-e415.
Kiefer C, Sturtz S, Bender R. 2015. Indirect Comparisons and Network Meta-Analyses. Dtsch Arztebl Int, 112, 803-808.
Kim ES, Hirsh V, Mok T et al., 2008. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet, 372, 1809-1818.
Lee DH, Park K, Kim JH et al., 2010. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res, 16: 1307-1314.
Lim E, Harris G, Patel A, Adachi I, Edmonds L et al., 2009. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. J Thorac Oncol, 4, 1380-1388.
Maruyama R, Nishiwaki Y, Tamura T et al., Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol, 26, 4244-4252.
Mok TS, Wu YL, Thongprasert S et al., 2009. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361, 947-957.
Morere JF, Brechot JM, Westeel V et al., 2010. Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study). Lung Cancer, 70, 301-307.
Qi WX, Shen Z, Lin F et al., 2012. Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 13, 5177-5182.
Rangachari D, Brahmer JR. 2013. Targeting the immune system in the treatment of non-small-cell lung cancer. Curr Treat Options Oncol, 14, 580-594.
Rittmeyer A, Barlesi F, Waterkamp D et al., 2017. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, 389, 255-265.
Shimanovsky A, Jethava A, Dasanu CA. 2013. Immune alterations in malignant melanoma and current immunotherapy concepts. Expert Opin Biol Ther, 13,1413-1427.
Sormani MP. 2017. Indirect comparisons of treatment effects: Network meta-analyses. Mult Scler, 23, 510-512.
Sun JM, Lee KH, Kim SW et al., 2012. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial. Cancer, 118, 6234-6242.
Sun Y, Wu YL, Li LY et al., 2011. Efficacy and safety of gefitinib or docetaxel in Chinese pa tients with locally advanced or metastatic non -small cell lung cancer (NSCLC) who had failed previous platinum -based first-line chemotherapy. Chin J Onco, 5, 377-380.
Sundar R, Soong R, Cho BC, Brahmer JR, Soo RA. 2014. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer, 85,101-109.
Vokes EE, Ready N, Felip E et al., 2018. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol, 29, 959-965.
Babo Zhang, XianDa Wang, Shuaifei Ji. 2019. PD-1/PD-L1 Antibody versus Gefitinib for Advanced Non-small Cell Lung Cancer: A Systematic Review and Network Meta-analysis of Randomized Control Trials. J Integral Sci, 2(2), 1-9.
Shuaifei Ji

Download Full Article

Abstracting & Indexing

Abstracting & Indexing (Under Process)